RT Journal Article
SR Electronic
T1 A gene expression map of host immune response in human brucellosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.01.22271720
DO 10.1101/2022.03.01.22271720
A1 Mitroulis, Ioannis
A1 Chrysanthopoulou, Akrivi
A1 Divolis, Georgios
A1 Ioannidis, Charalampos
A1 Ntinopoulou, Maria
A1 Tasis, Athanasios
A1 Konstantinidis, Theocharis
A1 Soteriou, Natalia
A1 Lallas, George
A1 Mitka, Stella
A1 Lesche, Mathias
A1 Dahl, Andreas
A1 Gembardt, Stephanie
A1 Panopoulou, Maria
A1 Sideras, Paschalis
A1 Wielockx, Ben
A1 Coskun, Ünal
A1 Ritis, Konstantinos
A1 Skendros, Panagiotis
YR 2022
UL http://medrxiv.org/content/early/2022/03/04/2022.03.01.22271720.abstract
AB Brucellosis is a common zoonotic disease caused by intracellular pathogens of the genus Brucella. Brucella infects macrophages and evades clearance mechanisms, which results in chronic parasitism. Herein, we studied the molecular changes that take place in human brucellosis both in vitro and in vivo. RNA sequencing was performed in primary human macrophages (Μφ) and polymorphonuclear neutrophils (PMNs) infected with clinical strains of B. melitensis. We observed a downregulation in the expression of genes involved in host response, such as TNF signaling, IL-1β production and phagosome formation in Μφ, and phosphatidylinositol signaling and TNF signaling in PMNs, being in line with the ability of the pathogen to survive within phagocytes. Further transcriptomic analysis of isolated peripheral blood mononuclear cells (PBMCs) and PMNs from patients with acute brucellosis before treatment initiation and after successful treatment revealed a positive correlation of the molecular signature of active disease with pathways associated with response to interferons (IFN). We identified 24 common genes that were significantly altered in both PMNs and PBMCs, including genes involved in IFN signaling that were downregulated after treatment in both cell populations, and IL1R1 that was upregulated. The levels of several inflammatory mediators were evaluated in the serum of these patients, and we observed increased levels of IFN-γ, IL-1β and IL-6 before the treatment of acute brucellosis. An independent cohort of patients with chronic brucellosis also revealed the increased levels of IFN-γ during relapse compared to remissions. Taken together, this study provides for the first time an in-depth analysis of the molecular alterations that take place in human phagocytes upon infection, and in peripheral blood immune populations during active disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the German Federal Ministry for Education and Research (BMBF) and Greek General Secretariat for Research and Technology (GSRT), German-Greek Bilateral Research & Innovation Programme BRIDGING, grant MIS 5030062, and partially was supported by the GSRT, Research & Innovation Programme CYTONET, grant MIS 5048548. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scientific and Ethics Committees of the University Hospital of Alexandroupolis, Greece (Number #1195/19/12/2017)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors